{
    "clinical_study": {
        "@rank": "9860", 
        "acronym": "POCER", 
        "arm_group": [
            {
                "arm_group_label": "group 1:surgery", 
                "description": "treatment = surgery only"
            }, 
            {
                "arm_group_label": "group 2: radiotherapy", 
                "description": "treatment = radiotherapy only"
            }, 
            {
                "arm_group_label": "group 3: RT and CT, and/or hyperthermia", 
                "description": "treatment=  radiotherapy combined with chemotherapy and/or hyperthermia"
            }, 
            {
                "arm_group_label": "group 4: stage IVb , any treatment", 
                "description": "cervical cancer stage IV b, treatment =  any systemic or radiation therapy and supportive care"
            }
        ], 
        "brief_summary": {
            "textblock": "The main aim is to validate and improve the predictive model for survival and toxicity in\n      patients with cervical cancer through multicentric prospective data collection. The data\n      contain information on patient, tumor and treatment characteristics. For this study,\n      additional health related QOL scores will be assessed using the EORTC Quality of Life\n      Questionair-CX24 and C30. The long term aim, beyond this specific study, is to build a\n      Decision Support System based on the predictive model validated in this study."
        }, 
        "brief_title": "Predicting Outcome in Cervix Carcinoma: a Prospective Study", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histological or cytological proven cervical cancer\n\n          -  informed consent according to national rules\n\n        Exclusion Criteria:\n\n          -  no histological or cytological proven cervical cancer\n\n          -  no informed consent according to national rules"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients with cervical cancer can be included in the study."
            }
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825005", 
            "org_study_id": "12-4-008"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cervical cancer", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ludy.lutgens@maastro.nl", 
                    "last_name": "L Lutgens, MD, PhD", 
                    "phone": "+31 88 44 55 666"
                }, 
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Maastricht University Hospital"
                }, 
                "investigator": {
                    "last_name": "P. Lambin, MD. PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "state": "Free State"
                    }, 
                    "name": "Bloemfontein medicross"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Netherlands", 
                "South Africa"
            ]
        }, 
        "number_of_groups": "4", 
        "official_title": "Predicting Outcome in Cervix Carcinoma: a Prospective Study", 
        "overall_contact": {
            "email": "ludy.lutgens@maastro.nl", 
            "last_name": "L. Lutgens, MD, PhD", 
            "phone": "+31 88 44 55 666"
        }, 
        "overall_contact_backup": {
            "email": "kitty.vangestel@maastro.nl", 
            "last_name": "C. van Gestel, MD", 
            "phone": "+ 31 88 44 55 666"
        }, 
        "overall_official": {
            "affiliation": "Maas tricht University hospital, dep of radiotherapy (Maastro clinic)", 
            "last_name": "P Lambin, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "assessment  of the overall survival 5 years after treatment", 
            "measure": "five-year overall survival rate", 
            "safety_issue": "No", 
            "time_frame": "5 years  after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825005"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "assessment of distant disease free survival, 3 years after treatment", 
                "measure": "three-year distant disease free survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "assessment of local disease free survival, 3 year after treatment", 
                "measure": "three-year local disease free survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "assessment of distant disease free survival,5 years after treatment", 
                "measure": "five-year distant disease free survival", 
                "safety_issue": "No", 
                "time_frame": "5  years"
            }, 
            {
                "description": "assessment of local disease free survival, 5 years after treatment", 
                "measure": "five-year local disease free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "number of participants with early adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "number of participants with late adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Maastricht Radiation Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maastricht Radiation Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "March 2014"
    }
}